Voyageur Pharmaceuticals Ltd., a Canadian public company trading on the TSXV, has recently granted 600,000 stock options to company officers as part of its incentive stock option plan. These options, priced at $0.06 per share, vest immediately and have a term of 10 years, pending regulatory and TSX Venture Exchange approval.
The company is focused on developing barium and iodine Active Pharmaceutical Ingredients (API) and providing high-performance, cost-effective imaging contrast agents. Voyageur aims to vertically integrate the barium and iodine contrast market by producing its own barium, iodine, and endo fullerenes. Through strategic partnerships with established third-party GMP pharmaceutical manufacturers in Canada, Voyageur plans to generate cash flow and validate its products with regulatory agencies worldwide. The company also plans to transition into a domestic manufacturer of radiology drugs to expand its revenue streams.
In addition to its business goals, Voyageur is committed to sustainability and environmental stewardship. The company intends to build state-of-the-art carbon-capture infrastructure using innovative technology to reduce carbon emissions. By investing in sustainable practices, Voyageur plans to generate revenue from carbon capture energy sources to drive growth and set itself apart as an industry leader.
Voyageur holds a 100% interest in the Frances Creek barium sulphate (barite) project, which aims to replace synthetic pharmaceutical barium sulphate with a higher quality, naturally sourced product. The company’s vision is to become the first fully integrated company in the radiology contrast media drug market, controlling all primary input costs from sourcing raw materials to final production to ensure quality and cost efficiency.
For further information, interested parties can contact Brent Willis, CEO, at Brent@vpharma.ca or Albert Deslauriers, CFO, at Albert@vpharma.ca. More information about Voyageur Pharmaceuticals Ltd. can be found at the company’s website.
Please note that the information in this press release contains forward-looking statements based on assumptions and future events. While the company provides no assurance that actual results will meet expectations, interested parties can find more information on the risks and uncertainties associated with forward-looking information in the company’s disclosure documents. Voyageur Pharmaceuticals Ltd. does not undertake to update any forward-looking information except as required by applicable securities laws.
(Source: Voyageur Pharmaceuticals Ltd.)
